DA-JC4
Based on 1 publication(s) in Google Scholar
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.27%
- No. CAS: 2315504-40-4
- Fòrmula: C225H346N56O65
- Peso molecular:4875.49
-
Almacenamiento:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DA-JC4
More
Actividad biológica
Descripciòn
IC50 & Target
GLP-1/GIP[1]
In Vitro
In Vivo
DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)[2].
DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (210–230 g)
-
Dosage:10 nmol/kg
-
Administration:I.p.
-
Result:Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus.
-
Animal Model:Adult male C57BL/6 mice (8 week-old)
-
Dosage:25 nmol/kg/day
-
Administration:I.p.
-
Result:Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF).
-
Animal Model:Adult male Sprague-Dawley (SD) rats (230-280 g)
-
Dosage:50 nmol/kg
-
Administration:I.p.
-
Result:Improved Parkinson's disease symptom potentially and enhanced neurotransmission.
Chemical Information
-
No. CAS 2315504-40-4
-
Appearance Solid
-
Peso molecular 4875.49
-
Fòrmula C225H346N56O65
-
Color White to off-white
-
Sequence
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Asp-Lys-Gln-Ala-Ala-{Aib}-Glu-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2
-
Sequence Shortening
Y-{Aib}-EGTFTSDYSIYLDKQAA-{Aib}-EFVNWLLAGGPSSGAPPPSKKKKKK-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
2024 Jun 10:2024.06.09.596693. PMID: 38915509
Solvente y solubilidad
In Vitro:
DMSO : 25 mg/mL (5.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74. [Content Brief]
[2]. Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2018;133:385-394. [Content Brief]
[3]. Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model. Life Sci. 2020;256:117824. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.2051 mL | 1.0255 mL | 2.0511 mL | 5.1277 mL |
| 5 mM | 0.0410 mL | 0.2051 mL | 0.4102 mL | 1.0255 mL |
DA-JC4 Related Classifications
HY-P3255 Related Classifications
Powered by Bioz